SE, Schuetz TJ, Kimura A A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (hunter syndrome) Mol Genet Metab 2007;90(3):329–337 46 Muenzer J, Wraith JE, Beck M, et al A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (hunter syndrome) Genet Med 2006;8(8):465–467 47 Bradley LA, Haddow HRM, Palomaki GE Treatment of mucopolysaccharidosis type II (hunter syndrome): results from a systematic evidence review Genet Med 2017 48 Fedele AO Sanfilippo syndrome: causes, consequences, and treatments Appl Clin Genet 2015;8:269–281 49 Gross DM, Williams JC, Caprioli C, Dominquez B, Howell RR Echocardiographic abnormalities in the mucopolysaccharide storage diseases Am J Cardiol 1988;61(1):170–176 50 Muenzer J, Beekman RH, Profera LM, Bove EL Severe mitral insufficiency in mucopolysaccharidosis type III-B (sanfilippo syndrome) Pediatr Cardiol 1993;14(2):130– 132 51 Di Natale P, Di Domenico C, Garqiulo N, et al Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviralNAGLU vector Biochem J 2005;388(Pt 2):639–646 52 John RM, Hunter D, Swantan RH Echocardiographic abnormalities in type IV mucopolysaccharidosis Arch Dis Child 1990;65:746–749 53 Kampmann C, Abu-Tair T, Gökce S, et al PLoS ONE 2016;11(9) [e0162612] 54 Tomatsu S, Gutierrez M, Nishioka T, et al Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase Hum Mol Genet 2005;14(22):3321–3335 55 Hayflick S, Rowe S, Kavanaugh-McHugh A, Olson JL, Valle D Acute infantile cardiomyopathy as a presenting feature of mucopolysaccharidosis VI J Pediatr 1992;120:269–272 56 Marwick TH, Bastian B, Hughes CF, Bailey BP Mitral stenosis in the Maroteaux–lamy syndrome: a treatable cause of dyspnoea Postgrad Med J 1992;68:287–288 57 Oudit GY, Butany J, Williams WG, Clarke JT, Iwanochko RM Images in cardiovascular medicine Left ventricular aneurysm associated with mucopolysaccharidosis type VI syndrome (maroteaux-lamy syndrome) Circulation 2007;115(5):e60–e62 58 Lakhotia S, Sharma A, Shrivastava GP, Jain SK Maroteaux-lamy syndrome Indian J Pediatr 2004;71(10):933–935 59 Kampmann C, Lampe C, Whybra-Trümpler C, et al Cardiac involvement and the impact of enzyme replacement therapy J Inherit Metab Dis 2014;37(2):269–276 60 Braunlin E, Rosenfeld H, Kampmann C, et al Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy J Inherit Metab Dis 2013;36(2):385–394 61 Mohan UR, Hay AA, Cleary MA, Wraith JE, Patel RG 2002 cardiovascular changes in children with mucopolysaccharide disorders Acta Paediatr 2002;91:799–804 62 Dangel JH Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders: clinical and echocardiographic findings in 64 patients Eur J Pediatr 1998;157:534–538 63 Gniadek TJ, Singer N, Barker NJ, et al Cardiovascular pathologies in mucopolysaccharidosis type VII (sly syndrome) Cardiovasc Pathol 2015;24(5):322–326